- Home
- MIR vs RYTM Comparison
MIR vs RYTM Comparison
Compare MIR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIR
- RYTM
- Stock Information
- Founded
- MIR 2005
- RYTM 2008
- Country
- MIR United States
- RYTM United States
- Employees
- MIR N/A
- RYTM N/A
- Industry
- MIR Industrial Machinery/Components
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MIR Technology
- RYTM Health Care
- Exchange
- MIR Nasdaq
- RYTM Nasdaq
- Market Cap
- MIR 3.3B
- RYTM 3.5B
- IPO Year
- MIR N/A
- RYTM 2017
- Fundamental
- Price
- MIR $14.11
- RYTM $50.79
- Analyst Decision
- MIR Strong Buy
- RYTM Strong Buy
- Analyst Count
- MIR 4
- RYTM 12
- Target Price
- MIR $19.25
- RYTM $68.42
- AVG Volume (30 Days)
- MIR 2.2M
- RYTM 507.5K
- Earning Date
- MIR 04-29-2025
- RYTM 05-06-2025
- Dividend Yield
- MIR N/A
- RYTM N/A
- EPS Growth
- MIR N/A
- RYTM N/A
- EPS
- MIR N/A
- RYTM N/A
- Revenue
- MIR $860,800,000.00
- RYTM $130,126,000.00
- Revenue This Year
- MIR $5.54
- RYTM $47.06
- Revenue Next Year
- MIR $7.44
- RYTM $68.10
- P/E Ratio
- MIR N/A
- RYTM N/A
- Revenue Growth
- MIR 7.48
- RYTM 68.06
- 52 Week Low
- MIR $9.11
- RYTM $35.17
- 52 Week High
- MIR $18.81
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- MIR 37.15
- RYTM 35.45
- Support Level
- MIR $14.33
- RYTM $50.12
- Resistance Level
- MIR $15.21
- RYTM $54.47
- Average True Range (ATR)
- MIR 0.73
- RYTM 2.38
- MACD
- MIR -0.12
- RYTM -0.45
- Stochastic Oscillator
- MIR 2.06
- RYTM 8.04
About MIR Mirion Technologies Inc.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.